(CCRN) Cross Country Healthcare - Overview
Stock: Nurse Staffing, Allied Staffing, Physician Staffing, Search Services
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 32.7% |
| Relative Tail Risk | -15.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.51 |
| Alpha | -60.78 |
| Character TTM | |
|---|---|
| Beta | 0.379 |
| Beta Downside | 0.587 |
| Drawdowns 3y | |
|---|---|
| Max DD | 73.43% |
| CAGR/Max DD | -0.42 |
Description: CCRN Cross Country Healthcare December 28, 2025
Cross Country Healthcare, Inc. (NASDAQ: CCRN) delivers talent-management solutions to U.S. healthcare providers through two primary segments: Nurse & Allied Staffing and Physician Staffing.
The Nurse & Allied Staffing segment covers a full spectrum of workforce services-including temporary and permanent placement of registered nurses, licensed practical nurses, certified nurse assistants, pharmacists, and other allied professionals-plus managed-service programs (MSP, VMS, RPO), education, in-home care, and outsourcing. It serves a broad client base ranging from acute-care hospitals and outpatient clinics to schools, correctional facilities, and PACE programs.
The Physician Staffing segment supplies physicians, certified registered nurse anesthetists, nurse practitioners, and physician assistants on a contract basis to acute and non-acute facilities, medical groups, government entities, and managed-care organizations.
Recent performance indicators show FY 2023 revenue of roughly $2.5 billion, a year-over-year growth rate of about 12 %, and an operating margin near 6 %, reflecting both strong demand for travel-nurse staffing amid a nationwide nurse shortage and pressure from rising labor costs. Key sector drivers include the aging U.S. population, expanding outpatient and home-based care, and ongoing Medicare reimbursement reforms that influence provider staffing budgets.
For a deeper dive into CCRN’s valuation metrics and scenario analysis, the ValueRay platform offers a concise, data-driven overview.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: -15.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -8.07 > 1.0 |
| NWC/Revenue: 18.59% < 20% (prev 14.91%; Δ 3.68% < -1%) |
| CFO/TA 0.10 > 3% & CFO 54.2m > Net Income -15.7m |
| Net Debt (-96.9m) to EBITDA (6.33m): -15.32 < 3 |
| Current Ratio: 3.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (32.5m) vs 12m ago -1.62% < -2% |
| Gross Margin: 20.19% > 18% (prev 0.21%; Δ 1998 % > 0.5%) |
| Asset Turnover: 198.6% > 50% (prev 242.4%; Δ -43.83% > 0%) |
| Interest Coverage Ratio: -4.55 > 6 (EBITDA TTM 6.33m / Interest Expense TTM 2.26m) |
Altman Z'' 5.33
| A: 0.39 (Total Current Assets 295.1m - Total Current Liabilities 85.5m) / Total Assets 538.2m |
| B: 0.38 (Retained Earnings 206.1m / Total Assets 538.2m) |
| C: -0.02 (EBIT TTM -10.3m / Avg Total Assets 567.8m) |
| D: 1.57 (Book Value of Equity 204.6m / Total Liabilities 130.1m) |
| Altman-Z'' Score: 5.33 = AAA |
Beneish M -3.34
| DSRI: 0.91 (Receivables 189.6m/267.2m, Revenue 1.13b/1.45b) |
| GMI: 1.04 (GM 20.19% / 20.91%) |
| AQI: 1.03 (AQ_t 0.40 / AQ_t-1 0.38) |
| SGI: 0.78 (Revenue 1.13b / 1.45b) |
| TATA: -0.13 (NI -15.7m - CFO 54.2m) / TA 538.2m) |
| Beneish M-Score: -3.34 (Cap -4..+1) = AA |
What is the price of CCRN shares?
Over the past week, the price has changed by -6.76%, over one month by +4.07%, over three months by -33.36% and over the past year by -52.25%.
Is CCRN a buy, sell or hold?
- StrongBuy: 0
- Buy: 0
- Hold: 7
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CCRN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.7 | 11.2% |
| Analysts Target Price | 9.7 | 11.2% |
| ValueRay Target Price | 6.9 | -20.6% |
CCRN Fundamental Data Overview February 03, 2026
P/S = 0.2708
P/B = 0.7477
P/EG = 3.802
Revenue TTM = 1.13b USD
EBIT TTM = -10.3m USD
EBITDA TTM = 6.33m USD
Long Term Debt = 2.20m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 846.0k USD (from shortTermDebt, last quarter)
Debt = 2.20m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -96.9m USD (from netDebt column, last quarter)
Enterprise Value = 208.4m USD (305.3m + Debt 2.20m - CCE 99.1m)
Interest Coverage Ratio = -4.55 (Ebit TTM -10.3m / Interest Expense TTM 2.26m)
EV/FCF = 4.56x (Enterprise Value 208.4m / FCF TTM 45.7m)
FCF Yield = 21.92% (FCF TTM 45.7m / Enterprise Value 208.4m)
FCF Margin = 4.05% (FCF TTM 45.7m / Revenue TTM 1.13b)
Net Margin = -1.39% (Net Income TTM -15.7m / Revenue TTM 1.13b)
Gross Margin = 20.19% ((Revenue TTM 1.13b - Cost of Revenue TTM 899.9m) / Revenue TTM)
Gross Margin QoQ = 20.37% (prev 20.43%)
Tobins Q-Ratio = 0.39 (Enterprise Value 208.4m / Total Assets 538.2m)
Interest Expense / Debt = 25.23% (Interest Expense 556.0k / Debt 2.20m)
Taxrate = 21.0% (US default 21%)
NOPAT = -8.12m (EBIT -10.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.45 (Total Current Assets 295.1m / Total Current Liabilities 85.5m)
Debt / Equity = 0.01 (Debt 2.20m / totalStockholderEquity, last quarter 408.1m)
Debt / EBITDA = -15.32 (Net Debt -96.9m / EBITDA 6.33m)
Debt / FCF = -2.12 (Net Debt -96.9m / FCF TTM 45.7m)
Total Stockholder Equity = 414.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -2.76% (Net Income -15.7m / Total Assets 538.2m)
RoE = -3.78% (Net Income TTM -15.7m / Total Stockholder Equity 414.4m)
RoCE = -2.47% (EBIT -10.3m / Capital Employed (Equity 414.4m + L.T.Debt 2.20m))
RoIC = -1.96% (negative operating profit) (NOPAT -8.12m / Invested Capital 414.4m)
WACC = 7.40% (E(305.3m)/V(307.5m) * Re(7.31%) + D(2.20m)/V(307.5m) * Rd(25.23%) * (1-Tc(0.21)))
Discount Rate = 7.31% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -3.17%
[DCF Debug] Terminal Value 73.05% ; FCFF base≈67.0m ; Y1≈44.0m ; Y5≈20.1m
Fair Price DCF = 16.37 (EV 439.3m - Net Debt -96.9m = Equity 536.2m / Shares 32.8m; r=7.40% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -96.01 | EPS CAGR: -64.11% | SUE: -0.25 | # QB: 0
Revenue Correlation: -97.63 | Revenue CAGR: -22.19% | SUE: -2.18 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.01 | Chg30d=-0.008 | Revisions Net=-1 | Analysts=5
EPS next Year (2026-12-31): EPS=0.10 | Chg30d=-0.080 | Revisions Net=-2 | Growth EPS=+4.7% | Growth Revenue=-5.4%